These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

480 related items for PubMed ID: 17720144

  • 1. Effects of nonpeptide vasopressin V2 antagonist tolvaptan in rats with heart failure.
    Veeraveedu PT, Watanabe K, Ma M, Palaniyandi SS, Yamaguchi K, Suzuki K, Kodama M, Aizawa Y.
    Biochem Pharmacol; 2007 Nov 15; 74(10):1466-75. PubMed ID: 17720144
    [Abstract] [Full Text] [Related]

  • 2. Effects of V2-receptor antagonist tolvaptan and the loop diuretic furosemide in rats with heart failure.
    Veeraveedu PT, Watanabe K, Ma M, Palaniyandi SS, Yamaguchi K, Kodama M, Aizawa Y.
    Biochem Pharmacol; 2008 Mar 15; 75(6):1322-30. PubMed ID: 18179782
    [Abstract] [Full Text] [Related]

  • 3. Tolvaptan, an orally active vasopressin V(2)-receptor antagonist - pharmacology and clinical trials.
    Miyazaki T, Fujiki H, Yamamura Y, Nakamura S, Mori T.
    Cardiovasc Drug Rev; 2007 Mar 15; 25(1):1-13. PubMed ID: 17445084
    [Abstract] [Full Text] [Related]

  • 4. Effects of novel vasopressin receptor antagonists on renal function and cardiac hypertrophy in rats with experimental congestive heart failure.
    Bishara B, Shiekh H, Karram T, Rubinstein I, Azzam ZS, Abu-Saleh N, Nitecki S, Winaver J, Hoffman A, Abassi ZA.
    J Pharmacol Exp Ther; 2008 Aug 15; 326(2):414-22. PubMed ID: 18467593
    [Abstract] [Full Text] [Related]

  • 5. Vasopressin V2-receptor blockade with tolvaptan in patients with chronic heart failure: results from a double-blind, randomized trial.
    Gheorghiade M, Niazi I, Ouyang J, Czerwiec F, Kambayashi J, Zampino M, Orlandi C, Tolvaptan Investigators.
    Circulation; 2003 Jun 03; 107(21):2690-6. PubMed ID: 12742979
    [Abstract] [Full Text] [Related]

  • 6. Mechanisms of the therapeutic effect of astragalus membranaceus on sodium and water retention in experimental heart failure.
    Ma J, Peng A, Lin S.
    Chin Med J (Engl); 1998 Jan 03; 111(1):17-23. PubMed ID: 10322646
    [Abstract] [Full Text] [Related]

  • 7. Long-term effects of nonpeptide vasopressin V2 antagonist OPC-31260 in heart failure in the rat.
    Burrell LM, Phillips PA, Risvanis J, Chan RK, Aldred KL, Johnston CI.
    Am J Physiol; 1998 Jul 03; 275(1):H176-82. PubMed ID: 9688911
    [Abstract] [Full Text] [Related]

  • 8. OPC-41061, a highly potent human vasopressin V2-receptor antagonist: pharmacological profile and aquaretic effect by single and multiple oral dosing in rats.
    Yamamura Y, Nakamura S, Itoh S, Hirano T, Onogawa T, Yamashita T, Yamada Y, Tsujimae K, Aoyama M, Kotosai K, Ogawa H, Yamashita H, Kondo K, Tominaga M, Tsujimoto G, Mori T.
    J Pharmacol Exp Ther; 1998 Dec 03; 287(3):860-7. PubMed ID: 9864265
    [Abstract] [Full Text] [Related]

  • 9. Current treatments and novel pharmacologic treatments for hyponatremia in congestive heart failure.
    Goldsmith SR.
    Am J Cardiol; 2005 May 02; 95(9A):14B-23B. PubMed ID: 15847853
    [Abstract] [Full Text] [Related]

  • 10. Vasopressin: a new target for the treatment of heart failure.
    Lee CR, Watkins ML, Patterson JH, Gattis W, O'connor CM, Gheorghiade M, Adams KF.
    Am Heart J; 2003 Jul 02; 146(1):9-18. PubMed ID: 12851603
    [Abstract] [Full Text] [Related]

  • 11. Vasopressin release, water channels, and vasopressin antagonism in cardiac failure, cirrhosis, and pregnancy.
    Schrier RW, Fassett RG, Ohara M, Martin PY.
    Proc Assoc Am Physicians; 1998 Jul 02; 110(5):407-11. PubMed ID: 9756091
    [Abstract] [Full Text] [Related]

  • 12. Effects of long-term oral treatment with selective vasopressin V2 receptor antagonist (OPC-31260) on adriamycin-induced heart failure in rats.
    Takeuchi M, Lee JD, Shimizu H, Ueda T.
    Int J Cardiol; 2006 Apr 04; 108(2):231-6. PubMed ID: 16002161
    [Abstract] [Full Text] [Related]

  • 13. Effects of tolvaptan on systemic and renal hemodynamic function in dogs with congestive heart failure.
    Onogawa T, Sakamoto Y, Nakamura S, Nakayama S, Fujiki H, Yamamura Y.
    Cardiovasc Drugs Ther; 2011 Dec 04; 25 Suppl 1():S67-76. PubMed ID: 22120095
    [Abstract] [Full Text] [Related]

  • 14. Development of high sodium renal hypertension during chronic blockade of the vascular effects of vasopressin.
    Hinojosa C, Haywood JR.
    J Pharmacol Exp Ther; 1986 Aug 04; 238(2):492-6. PubMed ID: 2874211
    [Abstract] [Full Text] [Related]

  • 15. Neurohormonal activation in congestive heart failure and the role of vasopressin.
    Chatterjee K.
    Am J Cardiol; 2005 May 02; 95(9A):8B-13B. PubMed ID: 15847852
    [Abstract] [Full Text] [Related]

  • 16. Effects of the V(2)-receptor antagonist OPC-41061 and the loop diuretic furosemide alone and in combination in rats.
    Hirano T, Yamamura Y, Nakamura S, Onogawa T, Mori T.
    J Pharmacol Exp Ther; 2000 Jan 02; 292(1):288-94. PubMed ID: 10604960
    [Abstract] [Full Text] [Related]

  • 17. Comparison of two aquaretic drugs (niravoline and OPC-31260) in cirrhotic rats with ascites and water retention.
    Bosch-Marcé M, Poo JL, Jiménez W, Bordas N, Leivas A, Morales-Ruiz M, Muñoz RM, Pérez M, Arroyo V, Rivera F, Rodés J.
    J Pharmacol Exp Ther; 1999 Apr 02; 289(1):194-201. PubMed ID: 10087004
    [Abstract] [Full Text] [Related]

  • 18. Tolvaptan improves left ventricular dysfunction after myocardial infarction in rats.
    Yamazaki T, Izumi Y, Nakamura Y, Yamashita N, Fujiki H, Osada-Oka M, Shiota M, Hanatani A, Shimada K, Iwao H, Yoshiyama M.
    Circ Heart Fail; 2012 Nov 02; 5(6):794-802. PubMed ID: 22984091
    [Abstract] [Full Text] [Related]

  • 19. Characterization of RWJ-351647, a novel nonpeptide vasopressin V2 receptor antagonist.
    Gunnet JW, Matthews JM, Maryanoff BE, de Garavilla L, Andrade-Gordon P, Damiano B, Hageman W, Look R, Stahle P, Streeter AJ, Wines PG, Demarest KT.
    Clin Exp Pharmacol Physiol; 2006 Apr 02; 33(4):320-6. PubMed ID: 16620295
    [Abstract] [Full Text] [Related]

  • 20. Aquaretic effect of lixivaptan, an oral, non-peptide, selective V2 receptor vasopressin antagonist, in New York Heart Association functional class II and III chronic heart failure patients.
    Abraham WT, Shamshirsaz AA, McFann K, Oren RM, Schrier RW.
    J Am Coll Cardiol; 2006 Apr 18; 47(8):1615-21. PubMed ID: 16630999
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 24.